GE holding on to life-science operations

Michael Walter | | Radiology Business | Economics

Jeffrey Immelt, GE’s chairman and CEO, has been busy reshaping the company so that it revolves more around heavy industry, but there appear to be no current plans to sell GE’s life-sciences business.

As reported by Bloomberg Business, GE is actually looking to grow that side of its business, which includes imaging, chromatography, cell-therapy tools, and more.

“It’s a fundamentally attractive industry with growth and we have a very strong competitive position,’’ said John Flannery, president and CEO of GE Healthcare, as quoted by Bloomberg Business. “We are certain this business grows faster inside of GE than it would grow outside.”

Click below for the full text from Bloomberg Business, which also goes on to summarize a lot of key information regarding GE’s continued transformation: 

GE to Keep Life-Science Unit Despite Shift to Heavy Industry

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers
Congress ditches doc fix in stopgap end-of-year funding bill
Teleradiology provider inks post-acute care deal worth $1.5M annually
US Radiology Specialists affiliate expands into new market
Radiologist rails against insurer’s refusal to cover key interventional service
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.